Kicking Cancer's Ass
"30 times more women die from breast cancer than need a liver transplant because of UPA. And yet the drug is paused." What if the drug that could prevent your breast cancer is already on pharmacy shelves — and regulators won't let your doctor prescribe it for that purpose? Dr. Sasha Howell, a medical oncologist from Manchester who runs one of the UK's leading breast cancer prevention programs, joined Kicking Cancer's Ass at the 2026 Rise Up Conference. His team's research, published in Nature in December, shows that three months of Ulipristal acetate reduced pre-cancerous cell proliferation and produced measurable changes in breast tissue on MRI. European regulators suspended the drug after five women in nearly a million developed liver failure. Statins and hormonal contraceptives carry higher risks and remain widely prescribed. This episode covers why two-thirds of women who develop breast cancer have no family history, what a polygenic risk score actually measures, and how clinical trial participation often means better monitoring than standard care. If you're worried about breast cancer risk, start with thewisdomstudy.org [http://thewisdomstudy.org] The Wisdom Study is open to anyone 30+ in the US who hasn't had breast cancer: thewisdomstudy.org. Polygenic risk scoring is available in the UK for roughly £500 (about $650 USD), though accessing someone who can interpret results and prescribe risk-reducing medication remains a gap almost everywhere outside specialized centers like Manchester. Kicking Cancer's Ass. We never chose the pitch, but we always choose the swing.
61 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Kicking Cancer's Ass!